MedTrace Logo

Ziprasidone in Children With Autism: A Pilot Study

NCT00208559 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2010-06-17

No results posted yet for this study

Summary

The purpose of this study is to see if the drug, ziprasidone, is effective in treating problems in adolescent associated with autism.

Conditions

Interventions

DRUG

Ziprasidone

Ziprasidone 40mg to 60mg per day, individually titrated

Sponsors & Collaborators

  • Drexel University College of Medicine

    lead OTHER

Principal Investigators

  • Richard P Malone, MD · Drexel University College of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2005-06-30
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00208559 on ClinicalTrials.gov